20/20 Biolabs, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from 20/20 Biolabs, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-25.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 61% of Healthcare companies in United States.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 79% of Healthcare companies in United States.
Tangible Assets Ratio
89%Of every $100 the company owns, $89 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 60% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
20/20 Biolabs, Inc. made a loss over the last year. 20/20 Biolabs, Inc. owes $0.74 for every $1 it owns. 20/20 Biolabs, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
Loss20/20 Biolabs, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.98The share price is 1.98 times 20/20 Biolabs, Inc.'s book value per share, lower than 59% of Healthcare companies in United States.
Market cap
$3 MThe total market value of all of 20/20 Biolabs, Inc.'s shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat 20/20 Biolabs, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.13Net worth divided by the number of shares. The share price of $0.25 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
-331.2%20/20 Biolabs, Inc. lost 331.2% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
Owes vs Owns
0.74×20/20 Biolabs, Inc. owes $0.74 for every $1 it owns (moderate), higher than 74% of Healthcare companies in United States.
Dividend yield
None20/20 Biolabs, Inc. does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Dec 2025.
Profit growth
Loss20/20 Biolabs, Inc. made a loss in each of the last two years.
Profit margin
-182.8%20/20 Biolabs, Inc. lost $183 for every $100 of revenue.
Interest cover
Not covered20/20 Biolabs, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debt20/20 Biolabs, Inc. had $0 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For 20/20 Biolabs, Inc.: $3 M ÷ $2 M (30 Jun 2026) = 2.0.
What is 20/20 Biolabs, Inc.'s return on equity?
20/20 Biolabs, Inc. lost 331.2% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
How much does 20/20 Biolabs, Inc. owe compared with what it owns?
20/20 Biolabs, Inc. owes $0.74 for every $1 it owns (moderate), higher than 74% of Healthcare companies in United States.
Does 20/20 Biolabs, Inc. pay a dividend?
No. 20/20 Biolabs, Inc. does not currently pay a dividend.
Is 20/20 Biolabs, Inc.'s revenue growing?
Revenue rose 17% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.